# Q&A: Advanced Oncotherapy PLC Steve Myers

- Link: https://www.directorstalkinterviews.com/qa-advanced-oncotherapy-plc-steve-myers/412730488
- Published: 2017-06-19T08:17:44+01:00
- Author: Giles Arbor

**Advanced Oncotherapy PLC** (LON:AVO) subsidiary ADAM S.A. Executive Chairman professor
Steve Myers talks to DirectorsTalk about the LIGHT system, it’s likely impact, the
design, the progress being made and its future.

**Q1: Professor Myers, you became Executive Chairman of ADAM S.A. (ADAM), the CERN
spin-off and Advanced Oncotherapy’s (AVO’s) subsidiary, in late 2015, and joined****
AVO’s Board earlier this year. Your primary responsibility is overseeing the development
of AVO’s proprietary and novel proton beam therapy (PBT) technology, LIGHT?**

**A1:** Yes, that’s right. The single most important aspect of LIGHT is that it 
is based on a fundamentally different design to all other PBT systems. All existing
technologies are based on cyclotrons or synchrotrons; LIGHT is the only linear proton
accelerator designed for medical application in the treatment of cancer.

**Q2: Does that matter?**

**A2:** It matters a great deal. These differences, in terms of technology and costs,
have major implications for LIGHT’s potential disruption of the global radiotherapy
market. Its technology provides a paradigm shift in clinical effectiveness: the 
speed at which the energy and direction of the beam can be modulated, the production
of secondary radiation, shielding requirements, beam size, size of magnets along
the beam transfer line and, hence, the size of the patient gantry, these are all
radically better with a linear accelerator.

Costs, in regards to upfront capital expenditure, ongoing maintenance and decommissioning,
have also proven prohibitively high for hospitals and clinics when considering existing
technologies. LIGHT will be available at a fraction of the cost of comparable competing
systems.

**Q3: So why aren’t there more linear proton accelerators in hospitals?**

**A3:** From a design perspective, it’s because the engineering behind LIGHT is 
sufficiently challenging that it has taken the expertise within ADAM, and the experience
of continually designing, creating and operating next-generation particle accelerators,
to build one.

**Q4: How has that expertise translated into LIGHT’s design; can you highlight some
examples?**

**A4:** There are a lot, but to pick just one of LIGHT’s components as an example,
in February ‘17 we reached a major technical milestone by hitting the desired output
energy from the RFQ (Radio Frequency Quadrupole). The RFQ has a number of unique
properties: operating at 750 MHz, so it is far smaller than comparable systems, 
and the energy of the proton beam can be altered 200 times every second, for more
accurate tumour targeting and adaptive treatment.

**Q5: So where are we with LIGHT?**

**A5:** We outlined the milestones we’re working towards at the investor evenings
in March 2017 and hitting those is very much our focus. We updated the market with
the progress we have made on the patient positioning system, ionisation chamber 
and RFQ on June 12th 2017; we’ll be providing further updates on milestones in due
course.

**Q6: So a major technical event will be generating a proton beam of sufficient 
energy to treat superficial tumours later in 2018?**

**A6:** That’s right.

**Q7: And then, once the first machine has been produced?**

**A7:** There is a huge, unmet medical need for new PBT systems and AVO has been
putting the foundations in place to cope with this demand. At the same time, we 
will keep innovating and continue leveraging LIGHT’s unique capabilities. A potential
future addition to LIGHT could be the ability to generate a beam of heavier ions,
with higher relative biological effectiveness than even protons. Other enhancements
could include enhanced accelerating power and, therefore, a shorter LIGHT system
or more efficient radiofrequency generators to reduce already low operating costs.
LIGHT’s modular nature lends itself perfectly to the possibility of upgrades and
to further improved clinical benefits and/or lower costs.

But, I should stress that the Advanced Oncotherapy PLC LIGHT is already sufficiently
different to existing technology to be hugely disruptive in the current market. 
Getting LIGHT into mass production is what we’ll be concentrating on.

Professor Steve Myers, Executive Chairman at ADAM S.A. thank you for Joining DirectorsTalk
today.

Share on:
